Motpoly Xr is a drug owned by Aucta Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 05, 2040. Details of Motpoly Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12042474 | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | Active |
| US11883374 | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | Active |
| US11337943 | Lacosamide pharmaceutical composition and dosage form thereof |
Jun, 2040
(15 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Motpoly Xr's patents.
Latest Legal Activities on Motpoly Xr's Patents
Given below is the list of recent legal activities going on the following patents of Motpoly Xr.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 24 May, 2022 | US11337943 |
| Patent Issue Date Used in PTA Calculation Critical | 24 May, 2022 | US11337943 |
| Email Notification Critical | 05 May, 2022 | US11337943 |
| Issue Notification Mailed Critical | 04 May, 2022 | US11337943 |
| Dispatch to FDC | 26 Apr, 2022 | US11337943 |
| Application Is Considered Ready for Issue Critical | 26 Apr, 2022 | US11337943 |
| Issue Fee Payment Verified Critical | 25 Apr, 2022 | US11337943 |
| Issue Fee Payment Received Critical | 25 Apr, 2022 | US11337943 |
| Mail Post Card | 03 Feb, 2022 | US11337943 |
| Email Notification Critical | 26 Jan, 2022 | US11337943 |
US patents provide insights into the exclusivity only within the United States, but Motpoly Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Motpoly Xr's family patents as well as insights into ongoing legal events on those patents.
Motpoly Xr's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Motpoly Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 05, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Motpoly Xr Generic API suppliers:
Lacosamide is the generic name for the brand Motpoly Xr. 30 different companies have already filed for the generic of Motpoly Xr, with Apotex having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Motpoly Xr's generic
Alternative Brands for Motpoly Xr
Motpoly Xr which is used for treating partial-onset seizures in adults and pediatric patients weighing at least 50 kg., has several other brand drugs using the same active ingredient (Lacosamide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Ucb Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Lacosamide, Motpoly Xr's active ingredient. Check the complete list of approved generic manufacturers for Motpoly Xr
About Motpoly Xr
Motpoly Xr is a drug owned by Aucta Pharmaceuticals Inc. It is used for treating partial-onset seizures in adults and pediatric patients weighing at least 50 kg. Motpoly Xr uses Lacosamide as an active ingredient. Motpoly Xr was launched by Aucta in 2023.
Approval Date:
Motpoly Xr was approved by FDA for market use on 04 May, 2023.
Active Ingredient:
Motpoly Xr uses Lacosamide as the active ingredient. Check out other Drugs and Companies using Lacosamide ingredient
Treatment:
Motpoly Xr is used for treating partial-onset seizures in adults and pediatric patients weighing at least 50 kg.
Dosage:
Motpoly Xr is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 200MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 150MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |